Revvity, Inc. (RVTY)RVTYRevvity, Inc.

SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Jul 22, 2026	Jul 22, 2026	View filing
25-NSE	Jul 20, 2026	Jul 20, 2026	View filing
11-K	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
SD	Jun 1, 2026	Jun 1, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 12, 2026	May 12, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
4	May 11, 2026	May 11, 2026	View filing
8-K	May 5, 2026	May 5, 2026	View filing
8-K	May 1, 2026	May 1, 2026	View filing
SC 13G	Apr 30, 2026	Apr 30, 2026	View filing
4	Apr 22, 2026	Apr 22, 2026	View filing
SC 13G/A	Mar 27, 2026	Mar 27, 2026	View filing
4	Mar 18, 2026	Mar 18, 2026	View filing
ARS	Mar 16, 2026	Mar 16, 2026	View filing
DEFA14A	Mar 16, 2026	Mar 16, 2026	View filing
DEF 14A	Mar 16, 2026	Mar 16, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
PRE 14A	Mar 6, 2026	Mar 6, 2026	View filing
4	Feb 26, 2026	Feb 26, 2026	View filing
4	Feb 25, 2026	Feb 25, 2026	View filing
10-K	Feb 24, 2026	Feb 24, 2026	View filing

About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Waltham, MA

11,000 employees

www.revvity.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Prahlad R. Singh

View full financials